Eli Lilly and Company $LLY Stock: Sound Income Strategies LLC Trims Holdings

Sound Income Strategies LLC lessened its position in Eli Lilly and Company (NYSE:LLY) by 62.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 2,209 shares of the company’s stock after selling 3,613 shares during the period. Sound Income Strategies LLC’s holdings in Eli Lilly and Company were worth $2,583,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Balefire LLC grew its position in shares of Eli Lilly and Company by 3.2% during the 3rd quarter. Balefire LLC now owns 4,398 shares of the company’s stock valued at $5,089,000 after acquiring an additional 136 shares during the period. Decker Wealth Management LLC lifted its stake in Eli Lilly and Company by 0.7% in the third quarter. Decker Wealth Management LLC now owns 16,906 shares of the company’s stock valued at $19,561,000 after purchasing an additional 113 shares during the last quarter. David J Yvars Group lifted its stake in Eli Lilly and Company by 1.1% in the third quarter. David J Yvars Group now owns 903 shares of the company’s stock valued at $1,045,000 after purchasing an additional 10 shares during the last quarter. Bullock Wealth Management Group grew its holdings in Eli Lilly and Company by 0.7% during the third quarter. Bullock Wealth Management Group now owns 2,983 shares of the company’s stock valued at $3,430,000 after purchasing an additional 21 shares during the period. Finally, Avaii Wealth Management LLC increased its position in Eli Lilly and Company by 51.5% in the third quarter. Avaii Wealth Management LLC now owns 2,522 shares of the company’s stock worth $2,883,000 after buying an additional 857 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Bank of America lifted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Leerink Partners increased their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Citigroup upped their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,313.43.

Eli Lilly and Company Trading Up 0.7%

Eli Lilly and Company stock opened at $1,177.57 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65. The stock has a market cap of $1.11 trillion, a P/E ratio of 39.52, a PEG ratio of 1.44 and a beta of 0.46. The firm’s fifty day moving average price is $1,174.35 and its 200-day moving average price is $1,097.02.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same period in the previous year, the business earned $6.31 earnings per share. The firm’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts forecast that Eli Lilly and Company will post 36.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: New Phase 3b TOGETHER-PsO data showed that combining Taltz with Zepbound produced broader biological effects than Taltz alone in adults with psoriasis and obesity. By Week 36, the combination changed 482 proteins versus 140 with Taltz alone and affected 467 genes versus 16, alongside improved skin clearance and weight loss. The findings could strengthen Lilly’s case for treating interconnected metabolic and inflammatory conditions. New Phase 3b data on Lilly’s Taltz and Zepbound
• Positive Sentiment: Analyst Cantor Fitzgerald raised its Eli Lilly price target to $1,440 from $1,410 and maintained an Overweight rating, implying meaningful upside based on continued obesity-drug demand and pipeline execution. Cantor Fitzgerald raises pharma price targets
• Positive Sentiment: Recent coverage continues to highlight strong Zepbound demand, potential retatrutide and Foundayo catalysts, and expansion in oncology and Alzheimer’s research. Lilly’s second-quarter revenue growth of roughly 48% and raised outlook provide fundamental support for the long-term growth narrative.
• Neutral Sentiment: Despite its growth profile, Lilly trades below its historical average forward earnings multiple. That may indicate a valuation opportunity, but it also reflects investor concerns about competition, pricing pressure and whether the company’s exceptional growth can continue.
• Neutral Sentiment: Lilly and Nvidia reportedly plan to commit up to $1 billion to an artificial-intelligence drug-discovery laboratory. The initiative may improve future research productivity, although it is unlikely to materially affect near-term earnings. Nvidia and Eli Lilly AI drug-discovery lab
• Negative Sentiment: Lilly’s largest shareholder filed to sell approximately $347 million of stock. The transaction may be routine portfolio management, but its size can raise concerns about insider or major-holder confidence and create additional supply.
• Negative Sentiment: The company is facing a lawsuit from a patient alleging stomach problems linked to Mounjaro and Trulicity. Litigation creates regulatory, legal and reputational risk, although the financial impact remains uncertain.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.